ORMP

Q: What is the price of Oramed Pharmaceuticals (ORMP) today?

The price of Oramed Pharmaceuticals (ORMP) today is $ 3.38, with return of 81.28% compared to the last year. The price of Oramed Pharmaceuticals (ORMP) started the year trading around $ 2.85 and today it is at $ 3.38. Follow the real-time price chart, the historical price of Oramed Pharmaceuticals (ORMP) and international markets.

Q: When does Oramed Pharmaceuticals (ORMP) pay dividends?

In the last year, Oramed Pharmaceuticals (ORMP) distributed dividends in the month of January, totaling $ 0.25. The Dividend Yield for the last 12 months is 7.31%.

Q: Is Oramed Pharmaceuticals (ORMP) worth it?

Currently, Oramed Pharmaceuticals (ORMP) is priced at $ 3.38, with a P/E of 3.27%, representing a deviation of 65% from its historical average P/E. In the last year, the stock showed a variation of 81.28 in its price and distributed $ 0.25 in dividends, resulting in a Dividend Yield of 7.31%. The total shareholder return was 81.28%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy Oramed Pharmaceuticals (ORMP) stock?

Investing in stocks of Oramed Pharmaceuticals (ORMP) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of Oramed Pharmaceuticals (ORMP) yield today?

The yield of Oramed Pharmaceuticals (ORMP) was 0.30% in the last month, 81.28% in the last year and -52.36% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.25 in dividends, with a Dividend Yield of 7.31%.If you wanted to buy 100 stocks of Oramed Pharmaceuticals (ORMP) today, the total investment would be $ 338.00, based on the current price of $ 3.38.If past performance were to repeat, the return on your investment would be:In 1 year: $ 612.73In 5 years: $ 161.02In 10 years: $ 183.74It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Oramed Pharmaceuticals Inc.

Price

$ 3.38

return (12m)

81.28%

p/e

3.27

p/b

0.71

DIVIDEND YIELD

7.31%

price ORMP

ORMP

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return of ORMP

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.30%

3 months

33.30%

1 year

81.28%

2 years

6.01%

5 years

-52.36%

10 years

-45.64%

Fundamentals ORMP

review the fundamentals of Oramed Pharmaceuticals shares

P/E

3.27

Sector: -3.72 Industry: -3.72

P/S (Price-to-Sales)

71.82

Sector: -3.83 Industry: -3.83

P/B

0.71

Sector: 1.99 Industry: 1.99

DIVIDEND YIELD (DY)

7.31%

Sector: - Industry: -

ROA

19.89%

Sector: -64.61% Industry: -64.61%

ROE

21.68%

Sector: -66.34% Industry: -66.34%

ROIC

-10.55%

Sector: -1,293.53% Industry: -1,293.53%

NET MARGIN

100.00%

Sector: -40.94% Industry: -40.94%

GROSS MARGIN

0.50%

Sector: 39.00% Industry: 39.00%

OPERATING MARGIN

-100.00%

Sector: -40.81% Industry: -40.81%

EV/EBITDA

2.46

Sector: -3.76 Industry: -3.76

EV/EBIT

2.46

Sector: -3.91 Industry: -3.91

PRICE-TO-ASSETS

0.65

Sector: 1.45 Industry: 1.45

BVPS

4.82

Sector: 1.76 Industry: 1.76

EPS

1.04

Sector: -2.03 Industry: -2.03

EQUITY-TO-ASSETS RATIO

0.92

Sector: 0.40 Industry: 0.40

LIABILITIES / ASSETS

0.08

Sector: 0.40 Industry: 0.40

CAGR REVENUE 5 YEARS

-5.76%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

FAIR VALUE OF Oramed Pharmaceuticals ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

$ 3.38

Fair Value

$ 0.00

Upside Return potential.

214.21%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ORMP

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/b	ROE	dy	market cap	net margin
JNJ	22.33	7.55	33.81%	2.07%	$ 598.47 B	28.46%
PFE	20.23	1.69	8.35%	6.22%	$ 157.22 B	12.42%
ABBV	97.04	0.00	0.00%	2.87%	$ 410.09 B	6.91%
NVO	10.62	5.47	51.50%	4.51%	$ 166.32 B	33.05%
MRK	16.84	0.00	0.00%	2.65%	$ 307.32 B	28.08%
AZN	31.62	6.64	20.99%	1.50%	$ 323.31 B	17.41%
GILD	21.74	8.18	37.62%	2.12%	$ 185.00 B	28.90%
BMY	18.00	-3.73	-20.72%	3.99%	$ 126.99 B	14.64%
ZTS	21.48	17.24	80.25%	1.53%	$ 57.42 B	28.23%
REGN	17.87	2.58	14.41%	0.45%	$ 80.51 B	31.41%
HALO	25.89	168.09	649.21%	0.00%	$ 8.20 B	22.69%
AMGN	27.13	24.16	89.06%	2.45%	$ 209.22 B	20.98%
MCK	27.98	-1,226.73	-4,383.84%	0.31%	$ 121.45 B	1.09%
VRTX	31.92	6.76	21.18%	0.00%	$ 126.19 B	32.94%
CAH	32.55	-20.04	-61.56%	0.89%	$ 54.10 B	0.68%
ADMA	17.77	8.63	48.57%	0.00%	$ 3.72 B	42.87%
BIIB	21.81	1.54	7.08%	0.00%	$ 28.20 B	13.07%
HRMY	8.91	1.98	22.24%	0.00%	$ 1.66 B	22.48%

Stock vs Index Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

ORMP Historical Dividends

current DY: 7.31%

5-year average DY: 7.31%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividend	01/16/2026	01/26/2026	0,25000000

ABOUT THE COMPANY Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc.

Average user rating I10

4.0 (1 people)

United States

24 years

Founded: 2002

2007

Time since IPO - 19 years

12

Employees

The Company Oramed Pharmaceuticals Inc. (United States), is listed on Nasdaq with a market value of $ 143.64 Millions, having an equity of $ 202.33 Millions.

With a total of 12 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 2.00 Millions, which generated a profit in the amount of $ 43.86 Millions.

As for its main indicators, the Company has a P/E ratio of 3.27, a P/BV ratio of 0.71 and in the last 12 months the dividend yield of ORMP was at 7.31%.

The Company is traded internationally through the ticker ORMP.

Market cap

$ 143.64 Millions

Net worth

$ 202.33 Millions

US$ 202,330,000.00

Assets

$ 220.49 Millions

US$ 220,490,000.00

Total Shares Outstanding

42.00 Millions

42,000,000

Average Daily Trading Volume

$ 223.61 Thousand

US$ 223,606.06

Sector

Health Care

Industry

Biotechnology

ORMP

ORMP revenue and profits

Financial Results ORMP

DRAG THE FRAME TO SEE MORE DATA

ORMP cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/B

0.00

MCK - McKesson

$ 995.69 55,47% (12M)

P/E

27.98

0.31%

ROE

-4,383.84%

P/B

-1,226.73

CAH - Cardinal Health

$ 226.35 81,86% (12M)

P/E

32.55

0.89%

ROE

-61.56%

P/B

-20.04

JNJ - Johnson & Johnson

$ 246.75 53,32% (12M)

P/E

22.33

2.07%

ROE

33.81%

P/B

7.55

PFE - Pfizer

$ 26.58 12,55% (12M)

P/E

20.23

6.22%

ROE

8.35%

P/B

1.69

ABBV - AbbVie

$ 233.86 17,21% (12M)

P/E

97.04

2.87%

ROE

0.00%

P/B

0.00

MRK - Merck & Co.

$ 119.83 35,27% (12M)

P/E

16.84

2.65%

ROE

0.00%

P/B

0.00

AZN - AstraZeneca

$ 201.76 34,78% (12M)

P/E

31.62

1.50%

ROE

20.99%

P/B

6.64

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 995.69 55,47% (12 M)

P/L

27.98

0.31%

ROE

-4,383.84%

P/VP

-1,226.73

CAH - Cardinal Health

$ 226.35 81,86% (12 M)

P/L

32.55

0.89%

ROE

-61.56%

P/VP

-20.04

JNJ - Johnson & Johnson

$ 246.75 53,32% (12 M)

P/L

22.33

2.07%

ROE

33.81%

P/VP

7.55

PFE - Pfizer

$ 26.58 12,55% (12 M)

P/L

20.23

6.22%

ROE

8.35%

P/VP

1.69

ABBV - AbbVie

$ 233.86 17,21% (12 M)

P/L

97.04

2.87%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 119.83 35,27% (12 M)

P/L

16.84

2.65%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$ 201.76 34,78% (12 M)

P/L

31.62

1.50%

ROE

20.99%

P/VP

6.64

Frequently Asked Questions

What is the price of Oramed Pharmaceuticals (ORMP) today?

The price of Oramed Pharmaceuticals (ORMP) today is $ 3.38, with return of 81.28% compared to the last year. The price of Oramed Pharmaceuticals (ORMP) started the year trading around $ 2.85 and today it is at $ 3.38. Follow the real-time price chart, the historical price of Oramed Pharmaceuticals (ORMP) and international markets.

When does Oramed Pharmaceuticals (ORMP) pay dividends?

In the last year, Oramed Pharmaceuticals (ORMP) distributed dividends in the month of January, totaling $ 0.25. The Dividend Yield for the last 12 months is 7.31%.

Is Oramed Pharmaceuticals (ORMP) worth it?

Currently, Oramed Pharmaceuticals (ORMP) is priced at $ 3.38, with a P/E of 3.27%, representing a deviation of 65% from its historical average P/E. In the last year, the stock showed a variation of 81.28 in its price and distributed $ 0.25 in dividends, resulting in a Dividend Yield of 7.31%. The total shareholder return was 81.28%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Oramed Pharmaceuticals (ORMP) stock?

Investing in stocks of Oramed Pharmaceuticals (ORMP) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Oramed Pharmaceuticals (ORMP) yield today?

The yield of Oramed Pharmaceuticals (ORMP) was 0.30% in the last month, 81.28% in the last year and -52.36% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.25 in dividends, with a Dividend Yield of 7.31%.

If you wanted to buy 100 stocks of Oramed Pharmaceuticals (ORMP) today, the total investment would be $ 338.00, based on the current price of $ 3.38.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 612.73
In 5 years: $ 161.02
In 10 years: $ 183.74

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

ORMP

Oramed Pharmaceuticals Inc.

Price

return (12m)

p/e

p/b

DIVIDEND YIELD

Return of ORMP

review the fundamentals of Oramed Pharmaceuticals shares

P/E

P/S (Price-to-Sales)

P/B

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 7.31%

5-year average DY: 7.31%

type

Ex - Dividend Date

payment date

value

ABOUT THE COMPANY Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc.

United States

24 years

2007

12

PROFIT X PRICE ORMP

Financial Results ORMP

ORMP cash flow

asset growth - ORMP

ORMP balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

Frequently Asked Questions